<DOC>
	<DOCNO>NCT01387269</DOCNO>
	<brief_summary>The administration Anamorelin patient Stage III-IV non-small cell lung cancer-cachexia ( NSCLC-C ) expect increase appetite , lean body mass , weight gain , muscle strength .</brief_summary>
	<brief_title>Safety Efficacy Anamorelin HCl Patients With Non-Small Cell Lung Cancer-Cachexia ( ROMANA 1 )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter study assess safety efficacy Anamorelin patient non-small cell lung cancer-cachexia ( NSCLC-C ) . The primary efficacy analysis include treatment difference change lean body mass physical function . Pharmacokinetic ( PK ) sample also collect Day 43 visit population PK .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Documented diagnosis unresectable Stage III Stage IV NSCLC Patients may receive maintenance chemotherapy Patients plan initiate new chemotherapy and/or radiation therapy regimen may within ± 14 day randomization Patients may complete chemotherapy and/or radiation therapy and/or plan initiate new regimen within 12 week randomization ; least 14 day must elapse completion chemotherapy and/or radiation therapy prior randomization Involuntary weight loss ≥5 % body weight within 6 month prior screen screen body mass index ( BMI ) &lt; 20 kg/m2 Body mass index ≤30 kg/m2 Life expectancy &gt; 4 month time screen ECOG performance status ≤2 Adequate hepatic function , define AST ALT level ≤5 x upper limit normal Adequate renal function , define creatinine ≤2 x upper limit normal , calculated creatinine clearance &gt; 30 ml/minute Ability understand comply procedure HGS evaluation If woman childbearing potential fertile man , he/she must agree use effective form contraception study 30 day follow last dose study drug ( effective form contraception abstinence , hormonal contraceptive , doublebarrier method ) Must willing able give sign informed consent , opinion Investigator , comply protocol test procedures Other form lung cancer ( e.g. , small cell , mesothelioma ) Women pregnant breastfeed Known HIV , hepatitis ( B &amp; C ) , active tuberculosis Had major surgery ( central venous access placement tumor biopsy consider major surgery ) within 4 week prior randomization ; patient must well recover acute effect surgery prior screen ; patient plan undergo major surgical procedure treatment period Currently take prescription medication intend increase appetite treat weight loss ; include , limited , testosterone , androgenic compound , megestrol acetate , methylphenidate , dronabinol Inability readily swallow oral tablet ; patient severe gastrointestinal disease ( include esophagitis , gastritis , malabsorption , obstructive symptom ) intractable frequent vomiting exclude Has active , uncontrolled infection Has uncontrolled diabetes mellitus Has untreated clinically relevant hypothyroidism Has know symptomatic brain metastasis Receiving strong CYP3A4 inhibitor within 14 day randomization Receiving tube feeding parenteral nutrition ( either total partial ) ; patient must discontinue treatment least 6 week prior Day 1 , throughout study duration Other clinical diagnosis , ongoing intercurrent illness Investigator 's opinion would prevent patient 's participation Has previous exposure Anamorelin HCl Patients actively receive concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>